GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins (Q38028654)

27 August 2017

title

GlycoFi's technology to control the glycosylation of recombinant therapeutic proteins (English)

1 reference

27 August 2017

1 reference

Alain Beck

1

1 reference

27 August 2017

Olivier Cochet

series ordinal

2

1 reference

27 August 2017

Thierry Wurch

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

Expert Opinion on Drug Discovery

27 August 2017

published in

1 reference

27 August 2017

volume

5

1 reference

27 August 2017

issue

1

1 reference

27 August 2017

page(s)

95-111

1 reference

Post-translational modifications in the context of therapeutic proteins

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Genetic defects in the human glycome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Getting the glycosylation right: implications for the biotechnology industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Differences in the glycosylation profile of a monoclonal antibody produced by hybridomas cultured in serum-supplemented, serum-free or chemically defined media

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Development and production of commercial therapeutic monoclonal antibodies in Mammalian cell expression systems: an overview of the current upstream technologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Glycosylation as a strategy to improve antibody-based therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Glycosylation engineering in yeast: the advent of fully humanized yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

The way forward, enhanced characterization of therapeutic antibody glycosylation: comparison of three level mass spectrometry-based strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

The impact of glycosylation on the biological function and structure of human immunoglobulins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Humanization of yeast to produce complex terminally sialylated glycoproteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Glycomics: a pathway to a class of new and improved therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Genome sequence of the recombinant protein production host Pichia pastoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Protein N-glycosylation in the baculovirus-insect cell system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

From planta to pharma with glycosylation in the toolbox.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Comparison of the methods for profiling glycoprotein glycans--HUPO Human Disease Glycomics/Proteome Initiative multi-institutional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Characterization of a complex glycoprotein whose variable metabolic clearance in humans is dependent on terminal N-acetylglucosamine content

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Glycosylation of recombinant antibody therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

An engineered human IgG1 antibody with longer serum half-life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Fc glycans terminated with N-acetylglucosamine residues increase antibody resistance to papain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Monoclonal antibodies as innovative therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Glycosylation of therapeutic proteins in different production systems.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Animal cell cultures: recent achievements and perspectives in the production of biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Production of humanized glycoproteins in bacteria and yeasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Expression of full-length immunoglobulins in Escherichia coli: rapid and efficient production of aglycosylated antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Synthesis and characterization of a functional intact IgG in a prokaryotic cell-free expression system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Selection, design, and engineering of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Isolation of full-length IgG antibodies from combinatorial libraries expressed in Escherichia coli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

High-level expression of recombinant IgG in the human cell line per.c6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Characterization by liquid chromatography combined with mass spectrometry of monoclonal anti-IGF-1 receptor antibodies produced in CHO and NS0 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Characterization of monoclonal antibody glycosylation: comparison of expression systems and identification of terminal alpha-linked galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Peptides as tools and drugs for immunotherapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Structural characterization of N-linked oligosaccharides on monoclonal antibody cetuximab by the combination of orthogonal matrix-assisted laser desorption/ionization hybrid quadrupole-quadrupole time-of-flight tandem mass spectrometry and sequentia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

The humanization of N-glycosylation pathways in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Challenges in therapeutic glycoprotein production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Cloning and disruption of the PpURA5 gene and construction of a set of integration vectors for the stable genetic modification of Pichia pastoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Cloning and disruption of the Pichia pastoris ARG1, ARG2, ARG3, HIS1, HIS2, HIS5, HIS6 genes and their use as auxotrophic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Recombinant human lactoferrin expressed in glycoengineered Pichia pastoris: effect of terminal N-acetylneuraminic acid on in vitro secondary humoral immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Engineering of an artificial glycosylation pathway blocked in core oligosaccharide assembly in the yeast Pichia pastoris: production of complex humanized glycoproteins with terminal galactose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Optimization of humanized IgGs in glycoengineered Pichia pastoris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Anti-Inflammatory Activity of Immunoglobulin G Resulting from Fc Sialylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Control of recombinant monoclonal antibody effector functions by Fc N-glycan remodeling in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Modulation of therapeutic antibody effector functions by glycosylation engineering: influence of Golgi enzyme localization domain and co-expression of heterologous beta1, 4-N-acetylglucosaminyltransferase III and Golgi alpha-mannosidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Efficient introduction of a bisecting GlcNAc residue in tobacco N-glycans by expression of the gene encoding human N-acetylglucosaminyltransferase III.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Development of a simple and rapid method for producing non-fucosylated oligomannose containing antibodies with increased effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Production of human monoclonal antibody in eggs of chimeric chickens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Selection of a human anti-RhD monoclonal antibody for therapeutic use: impact of IgG glycosylation on activating and inhibitory Fc gamma R functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

N-glycan modification in Aspergillus species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Role of complex asparagine-linked glycans in the allergenicity of plant glycoproteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Controlled glycosylation of therapeutic antibodies in plants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Analytical strategies to investigate plant N-glycan profiles in the context of plant-made pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

In vivo glyco-engineered antibody with improved lytic potential produced by an innovative non-mammalian expression system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Moss bioreactors producing improved biopharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

The N-linked sugar chains of human immunoglobulin G: their unique pattern, and their functional roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Higher levels of sialylated Fc glycans in immunoglobulin G molecules can adversely impact functionality

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Structures and functional roles of the sugar chains of human erythropoietins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

European Medicines Agency workshop on biosimilar monoclonal antibodies: July 2, 2009, London, UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Production of recombinant proteins in fermenter cultures of the yeast Pichia pastoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Simple high-cell density fed-batch technique for high-level recombinant protein production with Pichia pastoris: Application to intracellular production of Hepatitis B surface antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Process technology for production and recovery of heterologous proteins with Pichia pastoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Optimization of chemically defined medium for recombinant Pichia pastoris for biomass production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Temperature limited fed-batch technique for control of proteolysis in Pichia pastoris bioreactor cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Methanol induction optimization for scFv antibody fragment production in Pichia pastoris.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Production of functionalized single-chain Fv antibody fragments binding to the ED-B domain of the B-isoform of fibronectin in Pichia pastoris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Influence of specific growth rate on specific productivity and glycosylation of a recombinant avidin produced by a Pichia pastoris Mut strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Analysis and control of proteolysis of a fusion protein in Pichia pastoris fed-batch processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Engineering complex-type N-glycosylation in Pichia pastoris using GlycoSwitch technology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Economic issues with follow-on protein products

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Microbial factories for recombinant pharmaceuticals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Summary of recombinant human serum albumin development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

Sialylated therapeutic IgG: a sweet remedy for inflammatory diseases?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517/17460440903413504

10.1517/17460440903413504

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference